Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxil and Taxotere ± Herceptin in Advanced Breast Cancer
NCT00004888Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2001
- Primary completion
- Apr 2008
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pegylated liposomal doxorubicin in breast cancer (2 arms), sponsored by National Cancer Institute. Primary endpoints: Grades of Cardiotoxicity Events and Left Ventricular Ejection Fraction. Started Jan 2001; status: completed.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00004888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004888.